{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:30:53Z","timestamp":1784752253084,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":1919,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ad.2014.02.015","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T16:45:12Z","timestamp":1400517912000},"page":"923-934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Directrices del grupo espa\u00f1ol de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biol\u00f3gicos en pacientes con psoriasis en localizaciones de dif\u00edcil tratamiento (u\u00f1as, cuero cabelludo, palmas y plantas)"],"prefix":"10.1016","volume":"105","author":[{"given":"M.","family":"S\u00e1nchez-Rega\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Aldunce Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Belinch\u00f3n Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ribera Pibernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Lafuente-Urrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Carrascosa Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ferr\u00e1ndiz Foraster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Puig Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Daud\u00e9n Tello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vidal Sarr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fonseca Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Rodr\u00edguez Cerdeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Alsina Gibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Herrera Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Marr\u00f3n Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2014.02.015_bib0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ad.2013.04.003","article-title":"Directrices espa\u00f1olas basadas en la evidencia para el tratamiento de la psoriasis con agentes biol\u00f3gicos 2013. Consideraciones de eficacia y selecci\u00f3n del tratamiento","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2014.02.015_bib0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000232309","article-title":"Management of difficult to treat locations of psoriasis, scalp, face, flexures, palm\/soles and nails","volume":"38","author":"Kragballe","year":"2009","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0015","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clindermatol.2007.10.026","article-title":"Psoriasis treatment in difficult locations: Scalp, nails, and intertriginous areas","volume":"26","author":"Wozel","year":"2008","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0020","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4103\/0378-6323.72455","article-title":"Newer trends in the management of psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nails","volume":"76","author":"Handa","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2014.02.015_bib0025","series-title":"Psoriasis en los pliegues. Una parte del espectro de la psoriasis en \u00e1reas de piel sensible","author":"Martin Ezquerra","year":"2006"},{"key":"10.1016\/j.ad.2014.02.015_bib0030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0035","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2004.11.044","article-title":"Modification of the Nail psoriasis severity index","volume":"53","author":"Parrish","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200102030-00005","article-title":"Psoriasis of the scalp. Diagnosis and management","volume":"2","author":"Van de Kerkhof","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1046\/j.1365-2133.2001.04411.x","article-title":"Oral liarozole in the treatment of palmoplantar pustular psoriasis: A randomized, double-blind, placebo-controlled study","volume":"145","author":"Bhushan","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2009.03344.x","article-title":"Development and validation of nail psoriasis quality of life scale (NPQ10)","volume":"24","author":"Ortonne","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0001-7310(08)74613-1","article-title":"Aspectos diagn\u00f3sticos y terap\u00e9uticos de la psoriasis ungueal","volume":"99","author":"S\u00e1nchez-Rega\u00f1a","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2014.02.015_bib0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ad.2011.02.007","article-title":"Psoriasis ungueal en pacientes: estudio en 661 pacientes con psoriasis vulgar","volume":"102","author":"Armesto","year":"2011","journal-title":"Actas Dermosifiliogr"},{"issue":"Suppl 1","key":"10.1016\/j.ad.2014.02.015_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000316179","article-title":"Treatment and management of psoriasis with nail involvement: A focus on biologic therapy","volume":"221","author":"Langley","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000182250","article-title":"The nail as a musculoskeletal appendage\u2014implications for an improved understanding of the link between psoriasis and arthritis","volume":"218","author":"McGonagle","year":"2009","journal-title":"Dermatology"},{"issue":"Suppl 2","key":"10.1016\/j.ad.2014.02.015_bib0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0001-7310(12)70010-8","article-title":"Ustekinumab. Otros usos. Otras formas de psoriasis. Otras patolog\u00edas cut\u00e1neas","volume":"103","author":"S\u00e1nchez-Rega\u00f1a","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2014.02.015_bib0080","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1468-3083.2009.03474.x","article-title":"An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease","volume":"24","author":"Marchesoni","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0085","first-page":"CD007633","article-title":"Interventions for nail psoriasis","volume":"1","author":"De Vries","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2014.02.015_bib0090","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1468-3083.2010.03938.x","article-title":"Nail psoriasis: A retrospective study on the effectiveness of systemic treatments (classical and biological therapy)","volume":"25","author":"S\u00e1nchez-Rega\u00f1a","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0095","first-page":"1039","article-title":"Effectiveness of systemic treatment agents on psoriatic nails: A comparative study","volume":"12","author":"Odayakmaz Demirsoy","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib1100","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase iii, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2014.02.015_bib0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000317775","article-title":"Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: A retrospective analysis of the EXPRESS trial","volume":"221","author":"Reich","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1346-8138.2011.01459.x","article-title":"Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab","volume":"39","author":"Torii","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14712598.2013.736960","article-title":"TNF-\u03b1 antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis","volume":"13","author":"Saraceno","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2014.02.015_bib0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/09546634.2011.646939","article-title":"Anti-TNF agents and nail psoriasis: A single-center, retrospective, comparative study","volume":"24","author":"Kyriakou","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2014.02.015_bib0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2133.2008.08686.x","article-title":"Evaluation of the efficacy and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, open-label study","volume":"159","author":"Rigopoulos","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2004.09.012","article-title":"Remission and time of resolution of nail psoriasis during infliximab therapy","volume":"52","author":"Bianchi","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1468-3083.2010.03826.x","article-title":"Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients","volume":"25","author":"Fabroni","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0135","first-page":"1445","article-title":"The psoriatic patient profile for infliximab","volume":"15","author":"Gisondi","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ad.2014.02.015_bib0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2009.03211.x","article-title":"Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis","volume":"23","author":"Luger","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0145","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0150","first-page":"683","article-title":"Etanercept in the treatment and retreatment of psoriasis in daily clinical practice","volume":"18","author":"Barrera","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/ard.2010.135731","article-title":"Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: Are they effective?","volume":"70","author":"Otten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2014.02.015_bib0160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/0378-6323.74996","article-title":"Treatment of severe nail psoriasis with etanercept","volume":"77","author":"Coelho","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2014.02.015_bib0165","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1529-8019.2012.01472.x","article-title":"Marked improvement in nail psoriasis during treatment with etanercept","volume":"24","author":"G\u00f3mez V\u00e1zquez","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2014.02.015_bib0170","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1684\/ejd.2012.1863","article-title":"Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: Subanalysis of the BELIEVE study","volume":"22","author":"Paul","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib1180","article-title":"Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and\/or feet: Post hoc analysis of REACH","author":"Poulin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib1185","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","article-title":"Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions","volume":"69","author":"Van den Bosch","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2014.02.015_bib0180","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1468-3083.2009.03453.x","article-title":"Treatment of nail psoriasis with adalimumab: An open label unblinded study","volume":"24","author":"Rigopoulos","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/09546634.2010.519376","article-title":"Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice","volume":"23","author":"Sola-Ortigosa","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2014.02.015_bib0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000252853","article-title":"Marked improvement in nail psoriasis during treatment with adalimumab","volume":"219","author":"Irla","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0195","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2230.2007.02568.x","article-title":"Prevalence of fungal involvement in a series of patients with nail psoriasis","volume":"33","author":"S\u00e1nchez-Rega\u00f1a","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0200","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14712598.2013.783561","article-title":"Onychomycosis in patients of nail psoriasis on biologic therapy: A randomized, prospective open label study comparing etanercept, infliximab and adalimumab","volume":"13","author":"Al-Mutairi","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2014.02.015_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0210","article-title":"Improvement in nail psoriasis with ustekinumab, a new anti-IL-12\/23 P40 monoclonal antibody: Results from a phase 3 trial (PHOENIX I)","author":"Rich","year":"2008","journal-title":"EADV Abstract FP1007."},{"key":"10.1016\/j.ad.2014.02.015_bib0215","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0220","first-page":"96","article-title":"Ustekinumab in nail psoriasis: An open-label, uncontrolled, nonrandomized study","volume":"24","author":"Patsatsi","year":"2013","journal-title":"J DermatologTreat"},{"key":"10.1016\/j.ad.2014.02.015_bib0225","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-4632.2011.05320.x","article-title":"Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients","volume":"52","author":"Vitiello","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000339864","article-title":"Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: Case report and review","volume":"225","author":"Puig","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000017972","article-title":"Evaluation of topical drug treatment in psoriasis","volume":"197","author":"Van de Kerkhof","year":"1998","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0240","first-page":"536","article-title":"Psoriasis del cuero cabelludo","volume":"100","author":"Sola-Ortigosa S\u00e1nchez-Rega\u00f1a","year":"2009","journal-title":"ActasDermosifiliogr"},{"key":"10.1016\/j.ad.2014.02.015_bib0245","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1365-2133.2009.09238.x","article-title":"Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept","volume":"161","author":"Ortonne","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0250","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","article-title":"Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation","volume":"60","author":"Chan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0255","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","article-title":"Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept","volume":"67","author":"Bagel","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.ad.2014.02.015_bib0260","first-page":"AB120","article-title":"Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: Results from controlled clinical trials","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0265","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","article-title":"A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","volume":"56","author":"Moore","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0270","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1468-3083.2011.04394.x","article-title":"Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept","volume":"27","author":"Tyring","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1346-8138.2011.01312.x","article-title":"Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: Results in a single community-based hospital","volume":"39","author":"Noda","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0285","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1684\/ejd.2011.1499","article-title":"Rapid response of scalp psoriasis to ustekinumab","volume":"21","author":"Di Cesare","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1067\/S0190-9622(03)01479-8","article-title":"Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice","volume":"49","author":"Pettey","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0295","first-page":"407","article-title":"Nonpustular palmoplantar psoriasis","volume":"50","author":"Farber","year":"1992","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2014.02.015_bib0300","first-page":"CD001433","article-title":"Interventions for chronic palmoplantar pustulosis","author":"Marsland","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2014.02.015_bib0305","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2014.02.015_bib0310","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1468-3083.2011.03984.x","article-title":"Treatment of palmoplantar psoriasis with infliximab: A randomized, double-blind placebo-controlled study","volume":"25","author":"Bissonnette","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2014.02.015_bib0315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D327C5F5CF","article-title":"Successful treatment of hand and foot psoriasis with infliximab","volume":"16","author":"Di Lernia","year":"2010","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.ad.2014.02.015_bib0320","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1684\/ejd.2011.1567","article-title":"Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab","volume":"22","author":"Brunasso","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.ad.2014.02.015_bib0330","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2003.10.499","article-title":"Successful treatment of recalcitrant palmoplantar psoriasis with etanercept","volume":"50","author":"Weinberg","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0335","first-page":"940","article-title":"Etanercept in the treatment of palmoplantar pustulosis","volume":"7","author":"Bissonnette","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0340","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1525-1470.2011.01234.x","article-title":"Recalcitrant palmoplantar pustular psoriasis treated with etanercept","volume":"28","author":"Floristan","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0345","first-page":"e61","article-title":"Safety and efficacy of adalimumab in the treatment of moderate to severe palmoplantar psoriasis: An open label study","volume":"163","author":"Richetta","year":"2012","journal-title":"Clin Ter"},{"key":"10.1016\/j.ad.2014.02.015_bib0350","first-page":"1136","article-title":"Adalimumab in the management of palmoplantar psoriasis","volume":"8","author":"Ghate","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0355","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000167802","article-title":"Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab","volume":"218","author":"Yawalkar","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0360","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000320961","article-title":"Efficacy of ustekinumab in palmoplantar psoriasis","volume":"221","author":"Bulai Livideanu","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0365","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ad.2011.03.029","article-title":"Psoriasis hiperquerat\u00f3sica palmoplantar con excelente respuesta a ustekinumab","volume":"103","author":"Nu\u00f1o-Gonz\u00e1lez","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2014.02.015_bib0370","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/09546634.2012.672710","article-title":"Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis","volume":"24","author":"Au","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2014.02.015_bib0375","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/bjd.12150","article-title":"Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis","volume":"168","author":"Morales-M\u00fanera","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0380","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ad.2011.03.026","article-title":"Tratamiento de la pustulosis palmoplantar con ustekinumab","volume":"102","author":"De Unamuno-Bustos","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2014.02.015_bib0385","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1365-2133.2010.09897.x","article-title":"Ustekinumab in the treatment of palmoplantar pustulosis","volume":"163","author":"Gerdes","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0390","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000342503","article-title":"Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: Report of five cases and review of the literature","volume":"225","author":"Os\u00f3rio","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2014.02.015_bib0395","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","article-title":"Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-\u03b1 blocker agents. Report of five cases and review of the literature","volume":"25","author":"Ferran","year":"2011","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0400","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/DAD.0b013e3181ef7403","article-title":"Psoriatic alopecia\/alopecia areata-like reactions secondary to anti-tumor necrosis factor-\u03b1 therapy: A novel cause of noncicatricial alopecia","volume":"33","author":"Doyle","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ad.2014.02.015_bib0405","first-page":"700","article-title":"Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: Is it really a paradoxical side effect?","volume":"30","author":"Joyau","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0410","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/RHU.0b013e31823262c3","article-title":"Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis","volume":"17","author":"Safa","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ad.2014.02.015_bib0415","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0749-3797(01)00261-6","article-title":"Current methods of the U.S. Preventive Services Task Force: A review of the process","volume":"20","author":"Harris","year":"2001","journal-title":"Am J Prev Med"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731014002087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731014002087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:03:14Z","timestamp":1757552594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731014002087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0001731014002087"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2014.02.015","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Directrices del grupo espa\u00f1ol de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biol\u00f3gicos en pacientes con psoriasis en localizaciones de dif\u00edcil tratamiento (u\u00f1as, cuero cabelludo, palmas y plantas)","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2014.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}